Clinical Uses of Intrathecal Therapy and Its Placement in the Pain Care Algorithm

Pain Practice

Volumn 16, Issue 8, 2016, Pages 1092-1106

  Pope, Jason E ^a   Deer, Timothy R ^b   Bruel, Brian M ^c   Falowski, Steven ^d  

^a Summit Pain Alliance   (United States)

^b Center for Pain Relief   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d ST LUKE S UNIVERSITY HEALTH NETWORK   (United States)

Author keywords

algorithm; cancer pain; chronic pain; intrathecal analgesia; mixed pain; neuropathic; nociceptive; refractory pain; review

Indexed keywords

ANTICONVULSIVE AGENT; BUPIVACAINE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL N TYPE; DULOXETINE; HYDROCODONE; IBUPROFEN; METHADONE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA CONOTOXIN MVIIA; OPIATE; PARACETAMOL;

ADULT; ALLERGY; ANALGESIA; CASE REPORT; CHRONIC PAIN; CONFUSION; CONSERVATIVE TREATMENT; CONTINUOUS INFUSION; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DRUG DELIVERY DEVICE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ERYTHEMA; FEMALE; FLUOROSCOPY; GRANULOMA; HUMAN; LIFE EXPECTANCY; LONG TERM CARE; LOW DRUG DOSE; MEMORY DISORDER; NAUSEA; NEUROPATHIC PAIN; PATIENT CARE; PATIENT MONITORING; PATIENT SELECTION; PHYSIOTHERAPY; PSYCHOLOGIC ASSESSMENT; PSYCHOSIS; PSYCHOTHERAPY; QUALITY OF LIFE; RESPIRATION DEPRESSION; REVIEW; RISK BENEFIT ANALYSIS; SOMNOLENCE; SPINAL CORD STIMULATION; UNITED STATES; URINE RETENTION;

EID: 84959449395     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/papr.12438     Document Type: Review

References (118)

1. Institute of Medicine Committee on Advancing Pain Research Care and Education Board on Health Sciences Policy. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington, DC: The National Academies Press, 2011.
2. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2163–2196.
3. Deer TR, Smith HS, Cousins M, et al. Consensus guidelines for the selection and implantation of patients with noncancer pain for intrathecal drug delivery. Pain Physician. 2010;13:E175–E213.
4. Deer TR, Caraway DL, Wallace MS. A definition of refractory pain to help determine suitability for device implantation. Neuromodulation. 2014;17:711–715.
5. Hansson PT, Attal N, Baron R, Cruccu G. Toward a definition of pharmacoresistant neuropathic pain. Eur J Pain. 2009;13:439–440.
6. Hayek SM, Deer TR, Pope JE, Panchal SJ, Patel VB. Intrathecal therapy for cancer and non-cancer pain. Pain Physician. 2011;14:219–248.
7. Zamponi GW, Lewis RJ, Todorovic SM, Arneric SP, Snutch TP. Role of voltage-gated calcium channels in ascending pain pathways. Brain Res Rev. 2009;60:84–89.
8. Baldini A, Von Korff M, Lin EH. A review of potential adverse effects of long-term opioid therapy: a practitioner's guide. Prim Care Companion CNS Disord. 2012;14. pii: PCC.11m01326. doi:10.4088/PCC.11m01326.
9. Falowski S, Sharan A. A review on spinal cord stimulation. J Neurosurg Sci. 2012;56:287–298.
10. Pope JE, Deer TR, Kramer J. A systematic review: current and future directions of dorsal root ganglion therapeutics to treat chronic pain. Pain Med. 2013;14:1477–1496.
11. Pope JE, Falowski S, Deer TR. Advanced waveforms and frequency with spinal cord stimulation: burst and high-frequency energy delivery. Expert Rev Med Devices. 2015;12:431–437.
12. Krames E, Poree L, Deer T, Levy R. Implementing the SAFE principles for the development of pain medicine therapeutic algorithms that include neuromodulation techniques. Neuromodulation. 2009;12:104–113.
13. Wolter T. Spinal cord stimulation for neuropathic pain: current perspectives. J Pain Res. 2014;7:651–663.
14. Deer TR, Prager J, Levy R, et al. Polyanalgesic Consensus Conference 2012: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation. 2012;15:436–464.
15. Deer TR, Prager J, Levy R, et al. Polyanalgesic Consensus Conference–2012: recommendations on trialing for intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation. 2012;15:420–435.
16. Deer TR, Levy R, Prager J, et al. Polyanalgesic Consensus Conference–2012: recommendations to reduce morbidity and mortality in intrathecal drug delivery in the treatment of chronic pain. Neuromodulation. 2012;15:467–482.
17. INFUMORPH 200, INFUMORPH 500 (Preservative-free Morphine Sulfate Sterile Solution) [package insert]. Eatontown, NJ: West-Ward Pharmaceuticals, 2011.
18. Prialt (ziconotide) Solution, Intrathecal Infusion [package insert]. Palo Alto, CA: Jazz Pharmaceuticals, Inc., 2013.
19. Sanford M. Intrathecal ziconotide: a review of its use in patients with chronic pain refractory to other systemic or intrathecal analgesics. CNS Drugs. 2013;27:989–1002.
20. Wermeling DP. Ziconotide, an intrathecally administered N-type calcium channel antagonist for the treatment of chronic pain. Pharmacotherapy. 2005;25:1084–1094.
21. Pope JE, Deer TR. Intrathecal pharmacology update: novel dosing strategy for intrathecal monotherapy ziconotide on efficacy and sustainability. Neuromodulation. 2015;18:414–420.
22. ® Programmable Infusion Systems Clinical Reference Guide. Minneapolis, MN: Medtronic Neuromodulation, 2013.
23. Deer T, Winkelmuller W, Erdine S, Bedder M, Burchiel K. Intrathecal therapy for cancer and nonmalignant pain: patient selection and patient management. Neuromodulation. 1999;2:55–66.
24. Saulino M, Kim PS, Shaw E. Practical considerations and patient selection for intrathecal drug delivery in the management of chronic pain. J Pain Res. 2014;7:627–638.
25. Deer TR, Smith HS, Burton AW, et al. Comprehensive consensus based guidelines on intrathecal drug delivery systems in the treatment of pain caused by cancer pain. Pain Physician. 2011;14:E283–E312.
26. Rauck RL, Wallace MS, Leong MS, et al. Ziconotide 301 Study Group. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manage. 2006;31:393–406.
27. ® Programmable Pump. Neuromodulation. 2010;13:102–108.
28. Staats PS, Yearwood T, Charapata SG, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA. 2004;291:63–70.
29. Thimineur MA, Kravitz E, Vodapally MS. Intrathecal opioid treatment for chronic non-malignant pain: a 3-year prospective study. Pain. 2004;109:242–249.
30. Wallace MS, Charapata SG, Fisher R, et al. Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial. Neuromodulation. 2006;9:75–86.
31. De Andres J, Asensio-Samper JM, Fabregat-Cid G. Advances in intrathecal drug delivery. Curr Opin Anaesthesiol. 2013;26:594–599.
32. Henry-Feugeas MC, Idy-Peretti I, Baledent O, et al. Origin of subarachnoid cerebrospinal fluid pulsations: a phase-contrast MR analysis. Magn Reson Imaging. 2000;18:387–395.
33. Friese S, Hamhaber U, Erb M, Kueker W, Klose U. The influence of pulse and respiration on spinal cerebrospinal fluid pulsation. Invest Radiol. 2004;39:120–130.
34. Bernards CM. Recent insights into the pharmacokinetics of spinal opioids and the relevance to opioid selection. Curr Opin Anaesthesiol. 2004;17:441–447.
35. Bernards CM. Cerebrospinal fluid and spinal cord distribution of baclofen and bupivacaine during slow intrathecal infusion in pigs. Anesthesiology. 2006;105:169–178.
36. Flack SH, Anderson CM, Bernards C. Morphine distribution in the spinal cord after chronic infusion in pigs. Anesth Analg. 2011;112:460–464.
37. Yaksh TL, de Kater A, Dean R, Best BM, Miljanich GP. Pharmacokinetic analysis of ziconotide (SNX-111), an intrathecal n-type calcium channel blocking analgesic, delivered by bolus and infusion in the dog. Neuromodulation. 2012;15:508–519.
38. Arnow BA, Hunkeler EM, Blasey CM, et al. Comorbid depression, chronic pain, and disability in primary care. Psychosom Med. 2006;68:262–268.
39. Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Arch Intern Med. 2003;163:2433–2445.
40. Bair MJ, Wu J, Damush TM, Sutherland JM, Kroenke K. Association of depression and anxiety alone and in combination with chronic musculoskeletal pain in primary care patients. Psychosom Med. 2008;70:890–897.
41. Gureje O. Comorbidity of pain and anxiety disorders. Curr Psychiatry Rep. 2008;10:318–322.
42. Kroenke K, Outcalt S, Krebs E, et al. Association between anxiety, health-related quality of life and functional impairment in primary care patients with chronic pain. Gen Hosp Psychiatry. 2013;35:359–365.
43. McWilliams LA, Cox BJ, Enns MW. Mood and anxiety disorders associated with chronic pain: an examination in a nationally representative sample. Pain. 2003;106:127–133.
44. Low Y, Clarke CF, Huh BK. Opioid-induced hyperalgesia: a review of epidemiology, mechanisms and management. Singapore Med J. 2012;53:357–360.
45. Saxena AK, Arava SK. Current concepts in neuraxial administration of opioids and non-opioids: an overview and future perspectives. Indian J Anaesth. 2004;48:13–24.
46. Abram SE, Mampilly GA, Milosavljevic D. Assessment of the potency and intrinsic activity of systemic versus intrathecal opioids in rats. Anesthesiology. 1997;87:127–134.
47. Ruan X. Drug-related side effects of long-term intrathecal morphine therapy. Pain Physician. 2007;10:357–366.
48. Hayek SM, Veizi IE, Narouze SN, Mekhail N. Age-dependent intrathecal opioid escalation in chronic noncancer pain patients. Pain Med. 2011;12:1179–1189.
49. Coffey RJ, Owens ML, Broste SK, et al. Medical practice perspective: identification and mitigation of risk factors for mortality associated with intrathecal opioids for non-cancer pain. Pain Med. 2010;11:1001–1009.
50. Rauck RL, Wallace MS, Burton AW, Kapural L, North JM. Intrathecal ziconotide for neuropathic pain: a review. Pain Pract. 2009;9:327–337.
51. Kapural L, Lokey K, Leong MS, et al. Intrathecal ziconotide for complex regional pain syndrome: seven case reports. Pain Pract. 2009;9:296–303.
52. Webster LR, Fakata KL. Ziconotide for chronic severe pain. Pract Pain Manag. 2005;5:47–56.
53. Rauck RL, Caraway D, Leong MF, et al. Efficacy of Ziconotide in Patients Without Prior Intrathecal Therapy. Presented at: NY & NJSIPP 2014 Pain Medicine Symposium; November 6–9, 2014; Jersey City, NJ.
54. Veizi IE, Hayek SM, Narouze S, Pope JE, Mekhail N. Combination of intrathecal opioids with bupivacaine attenuates opioid dose escalation in chronic noncancer pain patients. Pain Med. 2011;12:1481–1489.
55. ®) to evaluate the option of continuous administration via an implanted intrathecal drug delivery (ITDD) system: a pilot study. Neuromodulation. 2013;16:576–581.
56. Coffey RJ, Owens ML, Broste SK, et al. Mortality associated with implantation and management of intrathecal opioid drug infusion systems to treat noncancer pain. Anesthesiology. 2009;111:881–891.
57. Deer TR, Provenzano DA. Recommendations for reducing infection in the practice of implanting spinal cord stimulation and intrathecal drug delivery devices: a physician's playbook. Pain Physician. 2013;16:E125–E128.
58. Prager J, Deer T, Levy R, et al. Best practices for intrathecal drug delivery for pain. Neuromodulation. 2014;17:354–372.
59. Pope JE, Deer TR. Ziconotide: a clinical update and pharmacologic review. Expert Opin Pharmacother. 2013;14:957–966.
60. Schmidtko A, Lötsch J, Freynhagen R, Geisslinger G. Ziconotide for treatment of severe chronic pain. Lancet. 2010;375:1569–1577.
61. Smith HS, Deer TR. Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain. Ther Clin Risk Manag. 2009;5:521–534.
62. Fisher R, Hassenbusch S, Krames E, et al. A consensus statement regarding the present suggested titration for prialt (ziconotide). Neuromodulation. 2005;8:153–154.
63. Flack SH, Bernards CM. Cerebrospinal fluid and spinal cord distribution of hyperbaric bupivacaine and baclofen during slow intrathecal infusion in pigs. Anesthesiology. 2010;112:165–173.
64. Medtronic Inc. Personal Therapy Manager for SynchroMed II: Physician Manual. 2007. http://professional.medtronic.com/wcm/groups/mdtcom_sg/@mdt/@neuro/documents/documents/idd-ptm8835-manl.pdf (accessed November 9, 2015).
65. Flowonix Medical. Flowonix Medical Inc. Announces FDA Approval of New Product. 2015. http://www.prnewswire.com/news-releases/flowonix-medical-inc-announces-fda-approval-of-new-product-300125380.html (accessed November 9, 2015).
66. Maeyaert J, Buchser E, Van Buyten JP, Rainov NG, Becker R. Patient-controlled analgesia in intrathecal therapy for chronic pain: safety and effective operation of the Model 8831 Personal Therapy Manager with a pre-implanted SynchroMed Infusion System. Neuromodulation. 2003;6:133–141.
67. Ilias W, le Polain B, Buchser E, Demartini L. Patient-controlled analgesia in chronic pain patients: experience with a new device designed to be used with implanted programmable pumps. Pain Pract. 2008;8:164–170.
68. ® (Ziconotide Intrathecal Infusion) for Patient-controlled Analgesia: A Case Series Highlighting Techniques and Outcomes. Presented at: 14th Annual Meeting of the North American Neuromodulation Society; December 2–5, 2010; Las Vegas, NV. http://www.slideserve.com/uri/use-of-the-personal-therapy-manager-with-prialt-ziconotide-intrathecal-infusion-for-patient-controlled-analgesia-case (accessed November 9, 2015).
69. McDowell GC, Mitchell J, Moore TD. Use of Intrathecal Ziconotide for Frequent Severe and Intractable Sickle Cell Disease-Related Pain. Presented at: 53rd ASH Annual Meeting and Exposition; December 10–13, 2011; San Diego, CA. http://oncology.by/uplds/ASH/MAC/webprogramcd/Paper43779.html (accessed November 9, 2015).
70. Deer TR. Pharmacology of intrathecal drug delivery in the spinal cord [abstract]. Reg Anesth Pain Med. 2014;39(5 suppl 1):e33–e34.
71. Patel VB, Manchikanti L, Singh V, Schultz DM, Hayek SM, Smith HS. Systematic review of intrathecal infusion systems for long-term management of chronic non-cancer pain. Pain Physician. 2009;12:345–360.
72. Falco FJ, Patel VB, Hayek SM, et al. Intrathecal infusion systems for long-term management of chronic non-cancer pain: an update of assessment of evidence. Pain Physician. 2013;16:SE185–SE216.
73. Duarte RV, Raphael JH, Southall JL, Baker C, Hanu-Cernat D. Intrathecal inflammatory masses: is the yearly opioid dose increase an early indicator? Neuromodulation. 2010;13:109–113.
74. Deer TR, Kim C, Bowman R, Tolentino D, Stewart C, Tolentino W. Intrathecal ziconotide and opioid combination therapy for noncancer pain: an observational study. Pain Physician. 2009;12:E291–E296.
75. Wallace MS, Kosek PS, Staats P, Fisher R, Schultz DM, Leong M. Phase II, open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of ziconotide in patients receiving intrathecal morphine for severe chronic pain. Pain Med. 2008;9:271–281.
76. Wallace MS, Rauck RL, Deer T. Ziconotide combination intrathecal therapy: rationale and evidence. Clin J Pain. 2010;26:635–644.
77. Webster LR, Fakata KL, Charapata S, Fisher R, Minehart M. Open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of morphine in patients receiving ziconotide for severe chronic pain. Pain Med. 2008;9:282–290.
78. Deer TR, Caraway DL, Kim CK, Dempsey CD, Stewart CD, McNeil KF. Clinical experience with intrathecal bupivacaine in combination with opioid for the treatment of chronic pain related to failed back surgery syndrome and metastatic cancer pain of the spine. Spine J. 2002;2:274–278.
79. Duarte RV, Raphael JH, Haque MS, Southall JL, Ashford RL. A predictive model for intrathecal opioid dose escalation for chronic non-cancer pain. Pain Physician. 2012;15:363–369.
80. Siddall PJ, Molloy AR, Walker S, Mather LE, Rutkowski SB, Cousins MJ. The efficacy of intrathecal morphine and clonidine in the treatment of pain after spinal cord injury. Anesth Analg. 2000;91:1493–1498.
81. Eastman MJ, Johnson SP. Interventional therapy: ziconotide combination intrathecal therapy. Pract Pain Manag. 2007;7:1–4.
82. Rainov NG, Heidecke V, Burkert W. Long-term intrathecal infusion of drug combinations for chronic back and leg pain. J Pain Symptom Manage. 2001;22:862–871.
83. Dupoiron D, Richard H, Chabert-Desnot V, Devys C, Leynia P, Boisdron-Celle M. In vitro stability of low-concentration ziconotide alone or in admixtures in intrathecal pumps. Neuromodulation. 2014;17:472–482.
84. Shields D, Montenegro R, Ragusa M. Chemical stability of admixtures combining ziconotide with morphine or hydromorphone during simulated intrathecal administration. Neuromodulation. 2005;8:257–263.
85. Shields D, Montenegro R. Chemical stability of ziconotide-clonidine hydrochloride admixtures with and without morphine sulfate during simulated intrathecal administration. Neuromodulation. 2007;10(suppl 1):6–11.
86. Shields D, Montenegro R, Aclan J. Chemical stability of an admixture combining ziconotide and bupivacaine during simulated intrathecal administration. Neuromodulation. 2007;10(suppl 1):1–5.
87. Shields D, Montenegro R, Aclan J. Chemical stability of admixtures combining ziconotide with baclofen during simulated intrathecal administration. Neuromodulation. 2007;10(suppl 1):12–17.
88. Shields D, Aclan A, Szatkowski A. Chemical stability of admixtures containing ziconotide 25 mcg/ml and morphine sulfate 10 mg/ml or 20 mg/ml during simulated intrathecal administration. Int J Pharm Compd. 2008;12:553–557.
89. Shields DE, Aclan J, Szatkowski A. Chemical stability of admixtures combining ziconotide with fentanyl or sufentanil during simulated intrathecal administration. Int J Pharm Compd. 2008;12:463–466.
90. Shields DE, Liu W, Gunning K, Montenegro R. Statistical evaluation of the chemical stability of ziconotide solutions during simulated intrathecal administration. J Pain Symptom Manage. 2008;36:e4–e6.
91. Abs R, Verhelst J, Maeyaert J, et al. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab. 2000;85:2215–2222.
92. Coffey RJ, Burchiel K. Inflammatory mass lesions associated with intrathecal drug infusion catheters: report and observations on 41 patients. Neurosurgery. 2002;50:78–86.
93. Cohen SP, Dragovich A. Intrathecal analgesia. Anesthesiol Clin. 2007;25:863–882, viii.
94. Miele VJ, Price KO, Bloomfield S, Hogg J, Bailes JE. A review of intrathecal morphine therapy related granulomas. Eur J Pain. 2006;10:251–261.
95. Duarte RV, Raphael JH, Southall JL, Labib MH, Whallett AJ, Ashford RL. Hypogonadism and low bone mineral density in patients on long-term intrathecal opioid delivery therapy. BMJ Open. 2013;3:e002856.
96. Deer TR, Krames E, Levy RM, Hassenbusch SJ III, Prager JP. Practice choices and challenges in the current intrathecal therapy environment: an online survey. Pain Med. 2009;10:304–309.
97. Hassenbusch S, Burchiel K, Coffey RJ, et al. Management of intrathecal catheter-tip inflammatory masses: a consensus statement. Pain Med. 2002;3:313–323.
98. Medtronic Inc. Updated Information—Inflammatory Mass (granuloma) At or Near the Distal Tip of Intrathecal Catheters. January, 2008. http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM135941.pdf (accessed July 21, 2015).
99. Zacest AC, Carlson JD, Nemecek A, Burchiel KJ. Surgical management of spinal catheter granulomas: operative nuances and review of the surgical literature. Neurosurgery. 2009;65:1161–1164.
100. Stearns L, Boortz-Marx R, Du PS, et al. Intrathecal drug delivery for the management of cancer pain: a multidisciplinary consensus of best clinical practices. J Support Oncol. 2005;3:399–408.
101. Burton AW, Fanciullo GJ, Beasley RD, Fisch MJ. Chronic pain in the cancer survivor: a new frontier. Pain Med. 2007;8:189–198.
102. Rauck RL, Cherry D, Boyer MF, Kosek P, Dunn J, Alo K. Long-term intrathecal opioid therapy with a patient-activated, implanted delivery system for the treatment of refractory cancer pain. J Pain. 2003;4:441–447.
103. Smith TJ, Staats PS, Deer T, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol. 2002;20:4040–4049.
104. Dupoiron D, Bore F, Lefebvre-Kuntz D, et al. Ziconotide adverse events in patients with cancer pain: a multicenter observational study of a slow titration, multidrug protocol. Pain Physician. 2012;15:395–403.
105. Alicino I, Giglio M, Manca F, Bruno F, Puntillo F. Intrathecal combination of ziconotide and morphine for refractory cancer pain: a rapidly acting and effective choice. Pain. 2012;153:245–249.
106. Kumar K, Malik S, Demeria D. Treatment of chronic pain with spinal cord stimulation versus alternative therapies: cost-effectiveness analysis. Neurosurgery. 2002;51:106–115.
107. Kumar K, Hunter G, Demeria DD. Treatment of chronic pain by using intrathecal drug therapy compared with conventional pain therapies: a cost-effectiveness analysis. J Neurosurg. 2002;97:803–810.
108. Kumar K, Taylor RS, Jacques L, et al. The effects of spinal cord stimulation in neuropathic pain are sustained: a 24-month follow-up of the prospective randomized controlled multicenter trial of the effectiveness of spinal cord stimulation. Neurosurgery. 2008;63:762–770.
109. Biggs SA, Duarte RV, Raphael JH, Ashford RL. Influence of a latent period in QALY analysis: pilot study of intrathecal drug delivery systems for chronic non-malignant pain. Br J Neurosurg. 2011;25:401–406.
110. Kumar K, Rizvi S, Bishop S. Cost effectiveness of intrathecal drug therapy in management of chronic nonmalignant pain. Clin J Pain. 2013;29:138–145.
111. Al-Kaisy A, Van Buyten JP, Smet I, Palmisani S, Pang D, Smith T. Sustained effectiveness of 10 kHz high-frequency spinal cord stimulation for patients with chronic, low back pain: 24-month results of a prospective multicenter study. Pain Med. 2014;15:347–354.
112. Deer TR, Grigsby E, Weiner RL, Wilcosky B, Kramer JM. A prospective study of dorsal root ganglion stimulation for the relief of chronic pain. Neuromodulation. 2013;16:67–71.
113. Liem L, Russo M, Huygen FJ, et al. A multicenter, prospective trial to assess the safety and performance of the spinal modulation dorsal root ganglion neurostimulator system in the treatment of chronic pain. Neuromodulation. 2013;16:471–482.
114. Liem L, Russo M, Huygen FJ, et al. One-year outcomes of spinal cord stimulation of the dorsal root ganglion in the treatment of chronic neuropathic pain. Neuromodulation. 2014;18:41–49.
115. de Ridder D, Vanneste S, Plazier M, van der Loo E, Menovsky T. Burst spinal cord stimulation: toward paresthesia-free pain suppression. Neurosurgery. 2010;66:986–990.
116. Van Buyten JP, Al-Kaisy A, Smet I, Palmisani S, Smith T. High-frequency spinal cord stimulation for the treatment of chronic back pain patients: results of a prospective multicenter European clinical study. Neuromodulation. 2013;16:59–65.
117. de Vos CC, Bom MJ, Vanneste S, Lenders MW, de Ridder D. Burst spinal cord stimulation evaluated in patients with failed back surgery syndrome and painful diabetic neuropathy. Neuromodulation. 2014;17:152–159.
118. Pope JE, Deer TR. Intrathecal drug delivery for pain: a clinical guide and future directions. Pain Manag. 2015;5:175–183.